Business Description
Humacyte Inc
NAICS : 325412
SIC : 2834
ISIN : US44486Q1031
Total Employee Number:
184Description
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.21 | |||||
Equity-to-Asset | 0.23 | |||||
Debt-to-Equity | 2.12 | |||||
Debt-to-EBITDA | -0.84 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -8.4 | |||||
Beneish M-Score | -3.76 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EPS without NRI Growth Rate | 4.8 | |||||
3-Year FCF Growth Rate | 1.4 | |||||
3-Year Book Growth Rate | -75.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 28.53 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 298.51 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 27.81 | |||||
9-Day RSI | 37.36 | |||||
14-Day RSI | 40.63 | |||||
3-1 Month Momentum % | -54.94 | |||||
6-1 Month Momentum % | -41.4 | |||||
12-1 Month Momentum % | -57.85 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.21 | |||||
Quick Ratio | 5.74 | |||||
Cash Ratio | 5.35 | |||||
Days Inventory | 347.19 | |||||
Days Sales Outstanding | 92.14 | |||||
Days Payable | 178.56 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -23.2 | |||||
Shareholder Yield % | -71.19 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -494.58 | |||||
Operating Margin % | -5240.78 | |||||
Net Margin % | -4560.82 | |||||
EBITDA Margin % | -3734.51 | |||||
FCF Margin % | -4599.72 | |||||
OCF Margin % | -4582.41 | |||||
ROE % | -1067.83 | |||||
ROA % | -81.25 | |||||
ROIC % | -177.87 | |||||
3-Year ROIIC % | 311.38 | |||||
ROC (Joel Greenblatt) % | -191.44 | |||||
ROCE % | -86.59 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 49.75 | |||||
PB Ratio | 5.42 | |||||
Price-to-Tangible-Book | 5.42 | |||||
EV-to-EBIT | -1.76 | |||||
EV-to-EBITDA | -1.92 | |||||
EV-to-Revenue | 71.67 | |||||
EV-to-Forward-Revenue | 3.34 | |||||
EV-to-FCF | -1.56 | |||||
Earnings Yield (Greenblatt) % | -56.82 | |||||
FCF Yield % | -58.87 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:HUMA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Humacyte Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2.121 | ||
| EPS (TTM) ($) | -0.51 | ||
| Beta | 5.0162 | ||
| 3-Year Sharpe Ratio | 0.1 | ||
| 3-Year Sortino Ratio | 0.18 | ||
| Volatility % | 103.21 | ||
| 14-Day RSI | 40.63 | ||
| 14-Day ATR ($) | 0.062282 | ||
| 20-Day SMA ($) | 0.659575 | ||
| 12-1 Month Momentum % | -57.85 | ||
| 52-Week Range ($) | 0.5261 - 2.55 | ||
| Shares Outstanding (Mil) | 277.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Humacyte Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Humacyte Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-12 08:00 | In 72 days | ||
| Third quarter earnings results for 2026 | 2026-11-12 | In 71 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-12 08:00 | 0.71 (-4.04%) | ||
| Second quarter earnings results for 2026 | 2026-08-12 | 0.71 (-4.04%) | ||
| Humacyte, Inc. Virtual Investor Event to Discuss Positive V012 Phase 3 Results In Which ATEV Outperformed Standard of Care In Female Dialysis Access Patients | 2026-06-15 17:00 | 1.06 (-4.09%) | ||
| General meeting for 2026 | 2026-06-09 08:00 | 1.38 (-1.43%) | ||
| First quarter earnings conference call for 2026 | 2026-05-13 08:00 | 0.91 (-6.19%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 0.91 (-6.19%) | ||
| Humacyte Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients | 2026-04-28 08:00 | 0.81 (+13.51%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-27 08:00 | 0.78 (-6.22%) |
Show
Entries
Humacyte Inc Frequently Asked Questions
What is Humacyte Inc(HUMA)'s stock price today?
The current price of HUMA is $0.60. The 52 week high of HUMA is $2.55 and 52 week low is $0.53.
When is next earnings date of Humacyte Inc(HUMA)?
The next earnings date of Humacyte Inc(HUMA) is 2026-11-12 Est..
Does Humacyte Inc(HUMA) pay dividends? If so, how much?
Humacyte Inc(HUMA) does not pay dividend.
Press Release
Articles on Humacyte Inc
Humacyte (HUMA) Reports Promising Phase 3 Trial Data Amidst Challenging Valuation Landscape
Aug 19, 2026
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers